[Sulacillin (a combination of ampicillin and sulbactam)--a new combined drug form for treatment of bacterial infections]. / Sulatsillin (sochetanie ampitsillina s sul'baktamom)--novaia kombinirovannaia lekarstvennaia forma dlia lecheniia bakterial'nykh infektsii.

The results of the cooperated clinical trial of sulacillin, a formulation including sodium ampicillin and sulbactam (2:1), are presented. The trial was carried out in different hospitals of Moscow and Smolensk. Rapid development of the favourable time course and recovery were stated in 93.7 per cent of the cases with upper and lower respiratory tract infections, urinary and biliferous tract infections, infections of the skin and soft tissues, gynecological infections and severe suppurative complications after surgical operations. Sulacillin is useful in the empirical therapy of purulent inflammatory diseases before the pathogen isolation and identification.

[Use of cefoperazone in clinical practice]. / Primenenie tsefoperazona v klinicheskoi praktike.

The bacteriological and clinical efficacy and side effects of cefoperazone were studied in 45 patients with severe and moderate purulent inflammatory diseases. The study showed that its bacteriological and clinical efficacy was high in cases with peritonitis, cholecystitis, respiratory and urinary infections, as well as those of the eye and soft tissues. The general clinical efficacy amounted to 95.6 per cent. The number of the side effects was insignificant. This made it possible to recommend the use of cefoperazone in the therapy of many purulent inflammatory diseases, as well as in empirical therapy.